



# **HLA-DQA1 3'UTR is an Unexplored Source of Disease Associations in the HLA Complex**

**Sonay Temurhan<sup>1</sup>, Fatma Savran Oguz<sup>1</sup>, Mehmet Tevfik Dorak<sup>2</sup>**

<sup>1</sup> Department of Medical Biology, Istanbul University Medical School, Istanbul, Turkey;

<sup>2</sup> School of Health Sciences, Liverpool Hope University, Liverpool, U.K.


**EFI 2015, Geneva**



**YOUR FUTURE  
STARTS WITH HOPE**



# BACKGROUND



The Wellcome Trust Centre for Human Genetics

## HLA Region:

- The most gene-dense and polymorphic
- Shows the highest number of disease associations

Most associations are attributed to variation in antigen presentation caused by polymorphisms




# BACKGROUND

Elsewhere in the genome, the most common *intermediate phenotype* between a polymorphism and disease development is alterations in gene expression regulation



# BACKGROUND



**Figure 11.2** The anatomy of a gene. This figure illustrates some of the key regulatory regions that control the transcription, splicing and post-transcriptional processing of genes and transcripts. Polymorphisms in these regions should be investigated for functional effects


## 11

### Predictive Functional Analysis of Polymorphisms: An Overview

Mary Plumpton<sup>1</sup> and Michael R. Barnes<sup>2</sup>


<sup>1</sup>Bioinformatics, GlaxoSmithKline Pharmaceuticals, <sup>1</sup> Stevenage, Hertfordshire, UK,

<sup>2</sup>Harlow, Essex, UK



# BACKGROUND

Of the genes encoding six classical HLA antigens, *HLA-DQA1* 3'UTR (<6.3kb) has the highest number of variants (n=769)



# AIM

To explore the polymorphism content of *HLA-DQA1* 3' UTR and potential functional consequences of these polymorphisms

# METHODS

**Functional annotation of *HLA-DQA1* 3'UTR variants using web-based bioinformatic tools and genome browsers**

1KG, Ensembl, HapMap, Illumina (NextBio) browser

AURA Atlas of UTR Regulatory Activity, JASPAR, dbSTEP

NCBI eQTL Browser, GTEx, RegulomeDB, miRBase

**Examination of disease associations by *HLA-DQA1* 3'UTR variants**

PheGenI, SNPnexus, GRASP



# RESULTS

## Summary of variation consequences in ENSG00000196735

[Switch to tree view](#)


Show All  entries

Filter

Number of variant consequences	Type	Description
0	-	Transcript ablation
12	Show	Splice donor variant
6	Show	Splice acceptor variant
1	Show	Stop gained
44	Show	Frameshift variant
0	-	Stop lost
0	-	Initiator codon variant
0	-	Transcript amplification
4	Show	Inframe insertion
8	Show	Inframe deletion
367	Show	Missense variant
76	Show	Splice region variant
0	-	Incomplete terminal codon variant
157	Show	Synonymous variant
0	-	Stop retained variant
4	Show	Coding sequence variant
0	-	Mature miRNA variant
92	Show	5 prime UTR variant
769	Show	3 prime UTR variant
998	Show	Non coding exon variant
5993	Show	Intron variant
1110	Show	NMD transcript variant
1698	Show	NC transcript variant
4839	Show	Upstream gene variant
4505	Show	Downstream gene variant
17787	Show	All



# RESULTS



# RESULTS

## AURA Atlas of UTR Regulatory Activity:


- 534 to 6246bp
- Transcript half life:
  - 291.2 to 395.1 minutes (Array probe ID: 211654\_X\_AT)
  - 435.8 to 463.9 minutes (Array probe ID: 212671\_S\_AT)

## Descriptive statistics:

- 668 SNPs
- 76 indel polymorphisms (one of which 167bp)
- 6 splice site SNPs (out of 49 in the whole of MHC in dbSTEP)
- 467 listed in NCBI dbSNP
- Only 2 in GWAS chips
- 14 observed in cancer genomes as somatic mutations




# RESULTS



# RESULTS

SNP	TFBS_id	chromStart_hg19	chromEnd_hg19	TFBS_Accession	TFBS_Species	TFBS_name	SwissProt_Accession
<a href="#">rs9272591</a>	V\$GATA_C	32607534	32607545	<a href="#">M00203</a>	human	GATA-1	<a href="#">P15976</a>
<a href="#">rs1129737</a>	V\$MYCMAX_01	32609087	32609101	<a href="#">M00118</a>	human	c-Myc	<a href="#">P01106</a>
<a href="#">rs1048134</a>	V\$AP1FJ_Q2	32609788	32609799	<a href="#">M00172</a>	human	c-Fos	<a href="#">P01100</a>
<a href="#">rs1048134</a>	V\$AP1FJ_Q2	32609788	32609799	<a href="#">M00172</a>	human	c-Jun	<a href="#">P05412</a>
<a href="#">rs41555012</a>	V\$AP1FJ_Q2	32609788	32609799	<a href="#">M00172</a>	human	c-Fos	<a href="#">P01100</a>
<a href="#">rs41555012</a>	V\$AP1FJ_Q2	32609788	32609799	<a href="#">M00172</a>	human	c-Jun	<a href="#">P05412</a>
<a href="#">rs1048173</a>	V\$MYCMAX_02	32609848	32609860	<a href="#">M00123</a>	human	c-Myc	<a href="#">P01106</a>



SNPnexus

Barts and The London  
School of Medicine and Dentistry

Barts  
Cancer Institute



# RESULTS

Human ▾ Location: 6:32,595,956-32,614,839 Gene: HLA-DQA1 Variation: rs71680105

Variation displays  
Explore this variation  
Genomic context  
Genes and regulation (12)  
Flanking sequence  
Population genetics  
Individual genotypes  
Linkage disequilibrium  
Phenotype Data  
Phylogenetic Context  
Citations  
External Data  
LOVD

Configure this page  
Add your data  
Export data  
Get VCF data  
Bookmark this page  
Share this page  
View in Ensembl  
Download view as CSV

**rs71680105 DELETION**

Original source Variants (including SNPs and indels) imported from dbSNP (release 138) | [View in dbSNP](#)

Alleles (LARGEDELETION)-

Location Chromosome 6:32610560-32610726 (forward strand) | [View in location tab](#)

HGVS names This variation has 6 HGVS names - click the plus to show

**Context**

**Structural variants display**

There are 430 structural variants overlapping this region. Some of them might not be displayed as we limit the size of each structural v

Genes (GENCODE 19)  
HLA-DQA1-001 > protein coding  
HLA-DQA1-004 > protein coding  
HLA-DQA1-007 > protein coding  
HLA-DQA1-009 > protein coding  
HLA-DQA1-002 > nonsense mediated decay  
HLA-DQA1-003 > retained intron

Contigs  
Sequence variants (...



dbSNP  
Short Genetic Variations



1000 Genomes  
A Deep Catalog of Human Genetic Variation

SubSNP Detail:  
NCBI Assay ID: ss99476824  
Submitter SNP ID: INDEL\_GP36\_2007a\_208672\_0  
Synonyms:  
LOCUSID:  
Submitter STS ID:  
STS Accession:  
GenBank Accession: NT\_007592  
Comment:

large deletion=  
aggtaagattgagactggttacagttgaagcggcagtatgaaaggaagga  
aagtggggaggcgctgtggacatgaatgtgggtaaagtttagggaaat  
tgggaagtggcatgtatgacacaggagccccctggaccattgtatc  
catgtctgcctgttc

# RESULTS

2 putative sites were predicted with these settings (95%) in sequence named DQA1

Model ID	Model name	Score	Relative score	Start	End	Strand	predicted site sequence
MA0130.1	ZNF354C	7.916	0.956240771454112	66	71	-1	gtccac
MA0133.1	BRCA1	7.329	0.951002797117118	161	167	-1	gcaacag

**Comment:** This type of analysis has a high sensitivity but abysmal selectivity. In other words: while true functional will be detected in most cases, most predictions will correspond to sites bound in vitro but with no function in vivo. A number of additional constraints of the analysis can improve the prediction; phylogenetic footprinting is the most common. We recommend using the [ConSite](#) service, which uses the JASPAR datasets.

The review [Nat Rev Genet. 2004 Apr;5\(4\):276-87](#) gives a comprehensive overview of transcription binding site prediction



# RESULTS

## dbSTEP

*Database of Splice Translational Efficiency Polymorphisms*


49 results for region chr6: 29 to 34MB

Variant	External ID	Intron	Alleles	Motif Position	Disease Impact	Minor Allele Freq	Allelic Score Difference	BLAST EST Evidence		Splice Prediction Difference		
								Unspliced	Spliced	HSF	NNSplice	NetUTR
rs2295665	BAT4	6:31740664..31741329	G/A	3' Splice Site	8.0225	0.164	1.0000	NO	NO	YES	YES	NO
rs2857692	BAT2	6:31696615..31698445	G/T	5' Splice Site	NULL	NULL	1.0000	NO	NO	YES	YES	YES
rs2857692	BAT2	6:31696615..31698482	G/T	5' Splice Site	NULL	NULL	1.0000	NO	NO	YES	YES	YES
rs9271906	HLA-DQA1	6:32704026..32707696	G/A	5' Splice Site	NULL	NULL	1.0000	NO	NO	YES	YES	NO
rs41544522	HLA-DPA1	6:33149466..33156434	G/T	5' Splice Site	NULL	NULL	1.0000	NO	NO	YES	YES	YES
rs41544522	HLA-DPA1	6:33149528..33156434	G/T	5' Splice Site	NULL	NULL	1.0000	NO	NO	YES	YES	YES
rs41544522	HLA-DPA1	6:33149425..33156434	G/T	5' Splice Site	NULL	NULL	1.0000	NO	NO	YES	YES	YES
rs56260633	TNXB	6:32157429..32157790	T/C	5' Splice Site	NULL	NULL	1.0000	NO	NO	YES	YES	YES
rs36224777	HLA-DQA1	6:32708665..32713175	G/A	3' Splice Site	NULL	NULL	1.0000	NO	YES	YES	YES	NO
rs3207966	HLA-DQA1	6:32708665..32713175	G/A	3' Splice Site	NULL	NULL	1.0000	NO	YES	YES	YES	NO

Four of them in *HLA-DQA1* 3' UTR

Variant	External ID	Intron	Alleles	Motif Position	Disease Impact	Minor Allele Freq	Allelic Score Difference	BLAST EST Evidence		Splice Prediction Difference		
								Unspliced	Spliced	HSF	NNSplice	NetUTR
rs36224777	HLA-DQA1	6:32708665..32713175	G/A	3' Splice Site	NULL	NULL	1.0000	NO	YES	YES	YES	NO
rs3207966	HLA-DQA1	6:32708665..32713175	G/A	3' Splice Site	NULL	NULL	1.0000	NO	YES	YES	YES	NO
rs9272426	HLA-DQA1	6:32708665..32713175	A/G	Polypyrimidine Tract	14.9176	0.422	0.0100	YES	YES	YES	YES	NO
rs36224778	HLA-DQA1	6:32708665..32713175	A/G	Polypyrimidine Tract	NULL	NULL	0.0100	YES	YES	YES	YES	NO

# RESULTS



# RESULTS

**eQTL Data**


1 - 2 of 2   [Download](#)   [Modify Search](#)

#	Tissue (Analysis ID)	rs#	SNP Location	Probe ID	Probe Location	Gene	P-value	R <sup>2</sup>
1	<a href="#">Lymphoblastoid (7)</a>	<a href="#">rs9272723</a>	<a href="#">6: 32,609,426</a>	<a href="#">GI_18426974-S</a>	<a href="#">6: 32,610,832</a>	<a href="#">HLA-DQA1</a>	<a href="#">4.183 x 10<sup>-47</sup></a>	0.6379
2	<a href="#">Liver (2)</a>	<a href="#">rs9272723</a>	<a href="#">6: 32,609,426</a>	<a href="#">HLA-DRB1</a>	<a href="#">6: 32,546,549</a>	<a href="#">HLA-DRB1</a>	<a href="#">2.430 x 10<sup>-39</sup></a>	

**OpheGenI**  
Phenotype-Genotype Integrator



**HapMap-CEU**  
Gene Expression by Genotype



NCBI Resources [eQTL Browser](#)

Genotype Marker rs9272723

Snp Id	Pvalue	PMID	LocationPhenotype	Phenotype Category	chr pos	InGene	Total Samples	Platform	
rs9272723	2.2E-75	<a href="#">17554300</a>	Webdata	Type 1 diabetes, Rheumatoid arthritis, combined case analysis, gender differentiated	Cardiovascular disease (CVD), Myocardial infarction (MI), Neuro, Behavioral, disorder, Blood pressure, CVD risk factor (CVD RF), Blood-related, Type 1 diabetes (T1D), Type 2 diabetes (T2D), Developmental, Arthritis, Crohn's disease	6 32641650	(HLA-DQA1)	4806	Affymetrix [469557]
rs9272723	1.2E-31	<a href="#">20453842</a>	FullScan	Rheumatoid arthritis	Inflammation, Arthritis, arthritis	6 32641650	(HLA-DQA1)	41282	Affymetrix & Illumina [ $\sim$ 271625] (imputed)
rs9272723	7.6E-17	<a href="#">21151127</a>	Text	Primary sclerosing cholangitis	Hepatic, Inflammation	6 32641650	(HLA-DQA1)	6539	Affymetrix [2466182] (imputed)
rs9272723	1.1E-11	<a href="#">20228798</a>	Table S3	Ulcerative colitis	Gastrointestinal, Inflammation, colitis	6 32641650	(HLA-DQA1)	10713	Affymetrix [1897764] (imputed)
rs9272723	1.7E-09	<a href="#">21156761</a>	Table S3	Rheumatoid arthritis (ACPA-positive)	Inflammation, Arthritis, arthritis	6 32641650	(HLA-DQA1)	9129	Illumina [1723056]
rs9272723	4.8E-09	<a href="#">20622879</a>	Table S2	Behcet's disease	Inflammation	6 32641650	(HLA-DQA1)	1607	Affymetrix [320438]

**P value for HLA-DQA1 eQTLs effect in GTEx is 10E-36.**

# RESULTS

## Complete Sequencing of *HLA-DQA1* 3'UTR and Correlations with Ancestral Lineages

Brittany A Morrison & M Tevfik Dorak

Genomic Immunoepidemiology Laboratory, HUMIGEN LLC, The Institute for Genetic Immunology, Hamilton, NJ 08690, USA

ASHI 2008

Samples	Splicing Donor Site	Splicing Acceptor Site 1	Splicing Acceptor Site 2	Splicing Acceptor Site 3
Ensembl 9	AA-GG-TAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
318	AA-GG-TAAGAT	CTGTTGC-AGGT	TCTCTCAAATTGTT	CATCCAGGG-
143	AA-GG-GTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
12	AA-GG-TAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
55	A--GG-TAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
105	A--GG-TAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
4	GAAGGGTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTTA	CATCCAGGG-
54	A---GTTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
8	AA---GTTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
11	AA---GTTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
14	AA---GTTAAGAT	CTGTTGC-TGGT	TCTCTCAAATGTT	CATCCAGGG-
53	GA---GTTAAGAT	CTGTTGC-TGGT	TCTCTCAAATGTT	CATCCAGGG-
1	AA---GTTAAGAT	CTGTTG-TTAC	TAGAGTAACTCTC	CATCCAGGG(
27	AA---GTTAAGAT	CTGTTG-CATGGT	TGTGTGTCAGGT	CATCCGGGG
107	AA---GTTAAGAT	CTGTTG-CATGGT	TCTCTCAGGT	CATCCGGGG
28	AA---GTTAAGAT	CTGTTG-CATGGT	TCTCTCAGGT	CATCCGGGG
146	AA---GTTAAGAT	CTGTTG-CATGGT	TCTCTCAGGT	CATCCGGGG
26	AA---GTTAAGAT	CTGTTG-CAAGGT	TCTCTCAGGT	CATCCGGGG
29	AA---GTTAAGAT	CTGTTG-CATGGT	TCTCTCAGGT	CATCCGGGG
90	AA---GTTAAGAT	CTGTTG-CATGGT	TGTGTGACAGGT	CATCCAGGG
31	AA---GTTAAGAT	CTGTTG-CATGGT	TCTCTCAGGT	CATCCGGGG
179	AA---GTTAAGAT	CTGTTGC-TGGT	TCTCTCAGGTGCT	CATACACGG-
68	AA---GTTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
69	AG---GTTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
35	A---GTTAAGAT	CTGTTAC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
20	A---GTTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
39	A---GTTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
23	A---GTTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
22	A---GTTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
42	A---GTTAAGAT	CTGTTGC-AGGT	TCTCTCAAATGTT	CATCCAGGG-
	* * *	*****	*	*** * *

Figure 4. HLA-DQA1 3'UTR sequences at functionally relevant parts of the HLA-DQA1 3'UTR. The cell lines belonging to the DRB4 lineage are marked at the splicing sites and they have a unique sequence in the splicing acceptor site 1.

Ensembl 9	AA-GG-TAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	261	Ensembl 731	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
318	AA-GG-TAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	107	9	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
143	AA-GG-GTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	3138	143	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
12	AA-GG-TAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	108	12	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
55	A--GG-TAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	111	12	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
105	A--GG-TAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	55	105	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
4	GAAGGGTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	233	55	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
54	A---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	55	4	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
8	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	219	54	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
11	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	111	8	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
14	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	111	11	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
53	GA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	121	14	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
1	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	116	1	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
27	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	212	27	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
107	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	107	107	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
28	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	213	28	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
146	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	203	146	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
26	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	203	26	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
29	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	211	29	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
90	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	209	90	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
31	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	208	31	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
27	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	292	27	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
107	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	212	107	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
28	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	185	28	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
146	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	213	146	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
26	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	203	26	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
29	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	211	29	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
90	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	209	90	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
31	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	208	31	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
68	AA---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	211	68	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
69	AG---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	103	69	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
35	A---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	103	35	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
20	A---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	142	20	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
39	A---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	111	39	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
23	A---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	161	23	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
22	A---GTTAAGAT-T-GAGACTGGTTACAGTG-AACCGGCA-TAGAACGAA-GAAAGTG	113	22	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
42	A---GTTAAGAT-T-GAGACTGGTTACAGTG-TACCTGCA-TAGAACGAA-GAAAGTG	157	42	CCTTATAGA-GATCTATGIAAAAATTTT---CCTATCTT-CATCCAGGG-CCTGATGAAACTA
	*****	*****	*	*****

Figure 3: HLA-DQA1 3' UTR sequencing results in a reference cell line panel representing ancestral lineages. The samples in the box are all of the DRB4 lineage samples in the panel. Indel polymorphisms exclusive to the DRB4 lineage are indicated in the sequence.



# CONSEQUENCES

Research


## Pervasive haplotypic variation in the spliceo-transcriptome of the human major histocompatibility complex

Claire Vandiedonck,<sup>1,2,3,5</sup> Martin S. Taylor,<sup>1,4</sup> Helen E. Lockstone,<sup>1</sup> Katharine Plant,<sup>1</sup> Jennifer M. Taylor,<sup>1</sup> Caroline Durrant,<sup>1</sup> John Broxholme,<sup>1</sup> Benjamin P. Fairfax,<sup>1</sup> and Julian C. Knight<sup>1,5</sup>

The human major histocompatibility complex (MHC) on chromosome 6p21 is a paradigm for genomics, showing remarkable polymorphism and striking association with immune and non-immune diseases. The complex genomic landscape of the MHC, notably strong linkage disequilibrium, has made resolving causal variants very challenging. A promising approach is to investigate gene expression levels considered as tractable intermediate phenotypes in mapping complex diseases. However, how transcription varies across the MHC, notably relative to specific haplotypes, remains unknown. Here, using an original hybrid tiling and splice junction microarray that includes alternate allele probes, we draw the first high-resolution strand-specific transcription map for three common MHC haplotypes (*HLA-A1-B8-Cw7-DR3*, *HLA-A3-B7-Cw7-DR5*, and *HLA-A26-B18-Cw6-DR3-DQ2*) strongly associated with autoimmune diseases including type 1 diabetes, systemic lupus erythematosus, and multiple sclerosis. We find that haplotype-specific differences in gene expression are common across the MHC, affecting 96 genes (46.4%), most significantly the zinc finger protein gene *ZFP57*. Differentially expressed probes are correlated with polymorphisms between haplotypes, consistent with *cis* effects that we directly demonstrate for *ZFP57* in a cohort of healthy volunteers ( $P = 1.2 \times 10^{-13}$ ). We establish that alternative splicing is significantly more frequent in the MHC than genome-wide (72.5% vs. 62.1% of genes,  $P \leq 1 \times 10^{-4}$ ) and shows marked haplotypic differences. We also unmask novel and abundant intergenic transcription involving 31% of transcribed blocks identified. Our study reveals that the renowned MHC polymorphism also manifests as transcript diversity, and our novel haplotype-based approach marks a new step toward identification of regulatory variants involved in the control of MHC-associated phenotypes and diseases.

Genome Res. 2011 21: 1042-1054

**Figure 1.** The first transcriptional map of the human MHC



# **CONCLUSIONS**

***HLA-DQA1 3'UTR is extremely polymorphic***


***There is evidence for the functionality of 3'UTR polymorphisms***

***There is almost no data on the phenotypical associations of these polymorphisms***

***The insufficiency of GWAS platforms to assess the roles played by these polymorphisms in disease susceptibility is obvious***

***Specially designed sequencing-based studies to unravel HLA region disease associations is desirable***





YOUR FUTURE  
STARTS WITH HOPE